Drug Shortage Report for ROPIVACAINE HYDROCHLORIDE INJECTION, USP

Last updated on 2023-11-17 History
Report ID 181157
Drug Identification Number 02439409
Brand name ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Common or Proper name ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) ROPIVACAINE HYDROCHLORIDE
Strength(s) 10MG
Dosage form(s) SOLUTION
Route of administration EPIDURAL EPIDURAL
Packaging size 20mL
ATC code N01BB
ATC description ANESTHETICS, LOCAL
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-01-01
Estimated end date 2023-11-15
Actual end date 2023-10-25
Shortage status Resolved
Updated date 2023-11-17
Company comments We will be facing a supply interruption on our Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL effective February 1, 2023 until November 15, 2023.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v12 2023-11-17 French Compare
v11 2023-11-17 English Compare
v10 2023-10-03 French Compare
v9 2023-10-03 English Compare
v8 2023-08-01 French Compare
v7 2023-08-01 English Compare
v6 2023-08-01 French Compare
v5 2023-08-01 English Compare
v4 2023-04-03 French Compare
v3 2023-04-03 English Compare
v2 2023-01-16 French Compare
v1 2023-01-16 English Compare

Showing 1 to 12 of 12